Brief: Foghorn Therapeutics Inc Says Reported Cash, Cash Equivalents And Marketable Securities Of $141.3 Mln As Of June 30, 2021

Foghorn Therapeutics

10/08/2021 12:17

Aug 10 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS INC. - REPORTED CASH, CASH
EQUIVALENTS AND
MARKETABLE SECURITIES OF $141.3 MILLION AS OF JUNE 30, 2021
    * FOGHORN - EXPECTS INITIAL DATA FROM CO'S PHASE 1 STUDIES
OF
FHD-286 IN BOTH METASTATIC UVEAL MELANOMA, RELAPSED/REFRACTORY
AML, MDS AS EARLY AS Q4
    * FOGHORN THERAPEUTICS INC. - EXPECTS INITIAL DATA FROM CO'S
PHASE
1 STUDY OF FHD-609 IN SYNOVIAL SARCOMA AS EARLY AS FIRST HALF OF
2022

Source text for Eikon:  ID:nGNX2yvhL2 
Further company coverage:  FHTX.O 

 ((reuters.briefs@thomsonreuters.com;))